Jalpa A. Doshi, PhD, is a Professor in the Division of General Internal Medicine and a Senior Fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania, where she is also Director of Value Based Insurance Design Initiatives at the Center for Health Incentives and Behavioral Economics and Director of the Economic Evaluations Unit of the Center for Evidence-based Practice. Prior to joining Penn, she obtained her PhD from the Department of Pharmaceutical Health Services Research at the University of Maryland.
Dr Doshi’s work applies health economics, outcomes research, and policy methods to address issues related to pharmaceutical access, costs, outcomes, and value. In recent years, her research program has particularly focused on specialty drugs for serious, rare, and/or chronic diseases. Her research and teaching also focus on advancing the methods used in pharmaceutical outcomes and cost-effectiveness research so as to enhance its usefulness in real-world decision making by patients, providers, payers, and policymakers. She has extensive experience working with data from administrative claims, surveys, registries, and clinical trials. She has coauthored Economic Evaluation in Clinical Trials (Oxford University Press), the first book dedicated entirely to this topic. Her research has received wide media attention and has informed policies of private insurers and government programs. Her work has been recognized by numerous awards, including new investigator awards (ISPOR, 2010; American Heart Association, 2008; American Geriatrics Society, 2008) and more than a dozen best research paper/abstract awards from ISPOR, AcademyHealth, Academy of Managed Care Pharmacy, Drug Information Association, and the Patient Access Network Foundation.
Dr Doshi has been an active contributor to ISPOR’s mission and activities for 15 years. She taught the short course on Statistical Methods in Health Economic Evaluations at the Annual International Meetings from 2005-2013 and has continued to teach the same course at the ISPOR Asia-Pacific Conferences since 2012. She was a member of the Task Force on Quality Improvement in Cost-Effectiveness Analysis (2006-2009) and more recently a member of the Steering Committee and Special Task Force for the ISPOR Initiative on US Value Assessment Frameworks (2016-2017). She has also served as a member and Chair of scientific achievement award committees for the Research Excellence Awards (2005-2010) and the Bernie O’Brien New Investigator Award (2011-2017). She has served as co-editor of Value in Health since 2011 and recently served as guest editor for its special issue on Value Assessment Frameworks, published in 2017.
ISPOR Vision Statement by Jalpa A. Doshi, PhD
I still remember attending my first ISPOR Annual International Meeting in the year 2000. In each year thereafter, it has been amazing to see ISPOR continually grow in terms of its membership size and diversity, commitment to promotion of high scientific standards, education and training programs, and communication and collaboration with various stakeholders. I feel fortunate to have been part of ISPOR’s journey over these years as a member, meeting attendee, abstract reviewer, session organizer, short course instructor, task force member, awards committee chair, and Value in Health editorial board member.
It would now be an honor to serve on the Board of Directors and to partner with our CEO, CSO, President, and other Board members to support ISPOR’s vision of being the leading global scientific and educational organization for health economics and outcomes research (HEOR) and its use in decision making to improve health. In particular, if elected I will help ISPOR lead efforts in three mission critical areas: (1) Advancing our science, (2) Translating our knowledge into practice, and (3) Cultivating future leaders. There has never been a more important time for ISPOR to be at the forefront of promoting HEOR excellence to improve healthcare decision making across the globe. As identified in the ISPOR 2018 Top 10 HEOR Trends report, we are facing a perfect storm of cost, value, and access issues due to unprecedented scientific breakthroughs, promising cell and gene therapies, the advent of biosimilars, an increasing number of countries considering universal health coverage, and so on. To take on these challenges, it is critical for us to link scientific rigor with dissemination efforts that ensure that our collective work has a central role in informing policy and practice. This will involve developing and improving methods and tools in health economics and outcomes research so that our work is able to address the full complexity of stakeholder concerns, as well as promoting understanding and highlighting its relevance to decision making at all levels in daily practice. At the same time as we seek to have a global impact of HEOR on decision making, it will be important to expand our education and training programs and to cultivate the next generation of HEOR leaders, especially as our growing 20000+ ISPOR membership spans 120+ countries.
I am truly committed to the science, communication, and mentorship necessary to achieve these goals and am excited to be considered as a Board Member.